Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months

Inclusion Criteria: * MS patients diagnosed with clinically definite MS according to the McDonald criteria (Polman et al., 2005) * Starting GA monotherapy (20mg/day sc) at the time of the OCT scan * Having baseline clinical OCT scan that included RNFLT and TMV assessment at the start of the GA * Having baseline clinical OCT scan that included RNFLT and TMV assessment (healthy controls) * MS patients having a RR disease course (Lublin and Reingold, 1996) * Age 18-65 (healthy controls will be matched to MS patients for age and sex) * Signed informed consent at the 24-month follow-up * None of the exclusion criteria Exclusion Criteria: * Patients who had a relapse within 30 days prior to OCT scan date * Patients who received steroid treatment within 30 days prior to OCT scan date * Women who are pregnant, lactating or of childbearing age who do not consent to approved contraceptive use during the study * MS patients who used other imunomodulatory or immunosuppressant treatment other than GA during the follow-up (e.g., IFN-β, mitoxantrone, cyclophosphamide, cladribine, fludarabine, cyclosporine, total body, azathioprine, methotrexate, IVIG, cellcept, natalizumab, etc.)